- Home
- PIRS vs TOI Comparison
PIRS vs TOI Comparison
Compare PIRS & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIRS
- TOI
- Stock Information
- Founded
- PIRS 2001
- TOI 2007
- Country
- PIRS United States
- TOI United States
- Employees
- PIRS N/A
- TOI N/A
- Industry
- PIRS Biotechnology: Pharmaceutical Preparations
- TOI Medical/Nursing Services
- Sector
- PIRS Health Care
- TOI Health Care
- Exchange
- PIRS Nasdaq
- TOI Nasdaq
- Market Cap
- PIRS 22.4M
- TOI 20.1M
- IPO Year
- PIRS N/A
- TOI N/A
- Fundamental
- Price
- PIRS $15.93
- TOI $0.16
- Analyst Decision
- PIRS
- TOI Strong Buy
- Analyst Count
- PIRS 0
- TOI 1
- Target Price
- PIRS N/A
- TOI $2.50
- AVG Volume (30 Days)
- PIRS 37.6K
- TOI 1.6M
- Earning Date
- PIRS 11-13-2024
- TOI 11-13-2024
- Dividend Yield
- PIRS N/A
- TOI N/A
- EPS Growth
- PIRS N/A
- TOI N/A
- EPS
- PIRS N/A
- TOI N/A
- Revenue
- PIRS $1,352,000.00
- TOI $378,933,000.00
- Revenue This Year
- PIRS N/A
- TOI $29.17
- Revenue Next Year
- PIRS N/A
- TOI $16.43
- P/E Ratio
- PIRS N/A
- TOI N/A
- Revenue Growth
- PIRS N/A
- TOI 22.29
- 52 Week Low
- PIRS $6.20
- TOI $0.13
- 52 Week High
- PIRS $22.32
- TOI $2.50
- Technical
- Relative Strength Index (RSI)
- PIRS 43.29
- TOI 28.86
- Support Level
- PIRS $15.15
- TOI $0.25
- Resistance Level
- PIRS $16.97
- TOI $0.25
- Average True Range (ATR)
- PIRS 0.72
- TOI 0.04
- MACD
- PIRS -0.08
- TOI -0.01
- Stochastic Oscillator
- PIRS 30.75
- TOI 14.80
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.